Enfusion, Inc. (NYSE:ENFN) Given Consensus Rating of “Reduce” by Brokerages

Shares of Enfusion, Inc. (NYSE:ENFN) have been assigned an average rating of “Reduce” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $9.33.

A number of brokerages have commented on ENFN. Bank of America boosted their price objective on Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a report on Wednesday, March 13th. The Goldman Sachs Group downgraded Enfusion from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $9.00 to $8.00 in a report on Wednesday, February 28th. Finally, Morgan Stanley began coverage on Enfusion in a research note on Friday, May 10th. They set an “overweight” rating and a $11.00 price objective on the stock.

Insider Buying and Selling

In related news, insider Bronwen Bastone sold 10,539 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $8.17, for a total value of $86,103.63. Following the transaction, the insider now directly owns 217,154 shares of the company’s stock, valued at approximately $1,774,148.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Enfusion news, Director Deirdre Somers sold 4,629 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $8.40, for a total transaction of $38,883.60. Following the completion of the transaction, the director now directly owns 43,312 shares of the company’s stock, valued at $363,820.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Bronwen Bastone sold 10,539 shares of Enfusion stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $8.17, for a total transaction of $86,103.63. Following the completion of the transaction, the insider now owns 217,154 shares of the company’s stock, valued at $1,774,148.18. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,318 shares of company stock worth $296,688. 36.44% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enfusion

Institutional investors have recently made changes to their positions in the stock. Barclays PLC boosted its stake in Enfusion by 29.0% during the third quarter. Barclays PLC now owns 10,809 shares of the company’s stock valued at $96,000 after buying an additional 2,430 shares during the period. Swiss National Bank grew its holdings in shares of Enfusion by 55.7% during the third quarter. Swiss National Bank now owns 49,500 shares of the company’s stock worth $444,000 after purchasing an additional 17,700 shares in the last quarter. Algert Global LLC bought a new position in shares of Enfusion in the third quarter worth approximately $139,000. Hudson Bay Capital Management LP increased its position in shares of Enfusion by 29.7% in the third quarter. Hudson Bay Capital Management LP now owns 460,084 shares of the company’s stock worth $4,127,000 after purchasing an additional 105,236 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Enfusion by 17.2% in the third quarter. Vanguard Group Inc. now owns 3,487,815 shares of the company’s stock valued at $31,286,000 after purchasing an additional 512,479 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Price Performance

Shares of Enfusion stock opened at $8.36 on Wednesday. Enfusion has a one year low of $7.52 and a one year high of $11.56. The business has a 50-day simple moving average of $9.11 and a 200 day simple moving average of $9.08. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of 278.76, a PEG ratio of 1.93 and a beta of 0.96.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The business had revenue of $48.05 million during the quarter, compared to the consensus estimate of $47.67 million. Enfusion had a net margin of 1.40% and a return on equity of 6.60%. During the same period last year, the business posted $0.04 earnings per share. On average, sell-side analysts expect that Enfusion will post 0.09 EPS for the current year.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.